The paper « Efficacy of a Novel Sublingual Spray Formulation of Artemether in African Children with Plasmodium falciparum Malaria » (Daryl Bendel et al.,Antimicrob. Agents Chemother. November 2015 vol. 59 no. 11 6930-6938) which was posted recently on www,malariaworld.org raises this important question. The clinical trials were run by an Australian pharmaceutical company in Burkina Faso, Rwanda and Ghana
It is in conflict with the WHO position « WHO urges regulatory authorities in malaria-endemic countries to take measures to halt the production and marketing of these oral monotherapies, and promote access to quality-assured artemisinin-based combination therapies (ACTs). The continued use of oral artemisinin-based monotherapies is considered to be a major contributing factor to the development of resistance to artemisinin derivatives.
Furthermore artemether in this drug is delivered in a spray of 6% artemether in coconut oil. But many health organizations advise against the consumption of coconut oil due to its high levels of saturated fat, including the United States Food and Drug Administration, World Health Organization, Coconut oil contains a large proportion of lauric acid, a saturated fat that raises total blood cholesterol levels.